NASDAQ$OMGAQ
Omega Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced third quarter 2021 financial results and outlined key corporate objectives.
Omega Therapeutics reported financial results for the third quarter ended September 30, 2021, highlighting the advancement of OTX-2002 through IND-enabling studies, a strategic collaboration with Stanford University School of Medicine, and a strong balance sheet with $234.3 million in cash and cash equivalents.
- OTX-2002, targeting c-MYC for hepatocellular carcinoma, is advancing through IND-enabling studies.
- A strategic collaboration was established with Stanford University School of Medicine for potential future Omega Epigenomic Controller development candidates.
- The company has a strong balance sheet with $234.3 million in cash and cash equivalents as of September 30, 2021.
- Completed a successful IPO, raising $141.1 million in aggregate gross proceeds.
Headline financials
Revenue & EPS history
Omega Therapeutics · Revenue · Quarterly
$2.61M
Forward guidance
Omega Therapeutics is focused on advancing its OMEGA platform and pipeline of Omega Epigenomic Controllers, with key objectives including filing an IND for OTX-2002 in the first half of 2022 and identifying additional development candidates.
Tailwinds
- Targeting filing an IND for OTX-2002 in the first half of 2022.
- Working on multiple programs in pre-clinical studies, including ARDS with CXCL1-3/IL8, alopecia with SFRP1, NSCLC with c-MYC and liver disease with HNF4a.
- Targeting the identification of additional development candidates for the first half of 2022 and an additional IND for the second half of 2022 or early 2023.
- Continuing to evolve and develop its OMEGA platform.
- Continual integration and updating of its suite of technologies that enable the development of potentially breakthrough medicines.
Headwinds
- The novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all
- The substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines
- The incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future
- Uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers
- Our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 9 quarterly earnings reports
-5.1%
Avg return
Earnings day
-8.9%
Avg return
5 days after
-12.9%
Avg return
30 days after
47%
7 / 15 earnings
Positive
+14.2%
Q1 2023
Best reaction
-47.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -47.5% | -25.0% | -44.8% | |
| Q3 2024 | -22.6% | -30.7% | -9.2% | |
| Q2 2024 | -0.6% | +0.0% | -11.3% | |
| Q1 2024 | -16.7% | -16.1% | -17.3% | |
| Q4 2023 | -9.9% | -15.3% | -36.6% | |
| Q3 2023 | -3.4% | +5.1% | +28.7% | |
| Q2 2023 | +2.4% | -14.2% | -23.8% | |
| Q1 2023 | +14.2% | +9.1% | +4.4% | |
| Q4 2022 | +5.6% | +7.0% | -6.7% | |
| Q3 2022 | -3.8% | — | — | |
| Q2 2022 | +9.3% | — | — | |
| Q1 2022 | +0.3% | — | — | |
| Q4 2021 | -6.4% | — | — | |
| Q3 2021 | +1.5% | — | — | |
| Q2 2021 | +0.9% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro